Compare ATOM & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATOM | ECOR |
|---|---|---|
| Founded | 2001 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 57.1M |
| IPO Year | 2016 | 2018 |
| Metric | ATOM | ECOR |
|---|---|---|
| Price | $2.37 | $7.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $25.50 |
| AVG Volume (30 Days) | ★ 428.2K | 75.1K |
| Earning Date | 02-10-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $38,000.00 | ★ $29,835,000.00 |
| Revenue This Year | N/A | $28.61 |
| Revenue Next Year | $300.00 | $41.21 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 27.90 |
| 52 Week Low | $1.89 | $4.16 |
| 52 Week High | $11.90 | $19.49 |
| Indicator | ATOM | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 49.99 | 80.31 |
| Support Level | $2.26 | $5.57 |
| Resistance Level | $2.45 | $6.67 |
| Average True Range (ATR) | 0.14 | 0.49 |
| MACD | 0.02 | 0.26 |
| Stochastic Oscillator | 59.09 | 96.17 |
Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used transistor types in the semiconductor industry. The mears silicon technology of the company can be used for applications like Analog, DRAM, logic and processors, and SRAM.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.